Hodgkin's Lymphoma

Text Size A A

E-Mail to a Friend



secret  Click to Play Audio


Send To Friend

Winning the Battle Against Lymphoma

There are many types and subtypes of lymphoma, each requiring a specialized treatment. Lymphoma patients who’ve chosen SCCA receive expertly targeted and delivered care, along with access to new therapies explored in clinical studies conducted at SCCA and its founding organizations, Fred Hutchinson Cancer Research Center and UW Medicine.

Statistics Are Abstract; Lives Aren’t

Pam Clark, Lymphoma Survivor In 2002 Pamela Clark was diagnosed with Hodgkin’s lymphoma at age 34. A bone marrow transplant in 2004 enabled to Pam to continue what she loves most, surfing up and down the Pacific Coast. Read more about Pam.

If you do have lymphoma, where you choose to go for initial treatment has a significant impact on your likelihood of survival. Lymphoma patients at SCCA have access to advanced therapies and treatments being explored in several dozen ongoing clinical trials for lymphoma conducted at SCCA’s founding organizations, Fred Hutchinson Cancer Research Center and UW Medicine. For people with lymphoma who are good candidates for stem cell transplants, the Fred Hutchinson Transplant program at SCCA is the most experienced transplant center in the world. As you can see below, patients treated for lymphoma at SCCA have high five-year survival rates.

Lymphoma Survival Rates

Below are the five-year survival rates for lymphoma patients treated by SCCA compared to patients who were treated for lymphoma elsewhere. This information was collected by the National Cancer Data Base (NCDB) for patients who were diagnosed between 1998 and 2002 and then followed for five years.

Stage I Lymphoma

  • SCCA patients are represented by the red line. Their five-year survival rate was 94 percent from the time they were first diagnosed by SCCA. Note that only patients who received all of their care from SCCA are included.
  • Patients from the other types of treatment centers—Community Cancer Centers, Comprehensive Community Cancer Centers, and Academic/Research Hospitals—are represented by blue, green, and yellow lines. Their five-year survival rates were between 69 and 73 percent.

Stage II Lymphoma

  • SCCA patients are represented by the red line. Their five-year survival rate was 86 percent from the time they were first diagnosed by SCCA. Note that only patients who received all of their care from SCCA are included.
  • Patients from the other types of treatment centers—Community Cancer Centers, Comprehensive Community Cancer Centers, and Academic/Research Hospitals—are represented by blue, green, and yellow lines. Their five-year survival rates were between 64 and 74 percent.

Stage IV Lymphoma

  • SCCA patients are represented by the red line. Their five-year survival rate was 68 percent from the time they were first diagnosed by SCCA. Note that only patients who received all of their care from SCCA are included.
  • Patients from the other types of treatment centers—Community Cancer Centers, Comprehensive Community Cancer Centers, and Academic/Research Hospitals—are represented by blue, green, and yellow lines. Their five-year survival rates were between 41 and 49 percent.

The NCDB tracks the outcomes of 70 percent of all newly diagnosed cancer in the United States from more than 1,500 commission-accredited cancer programs. It has been collecting data from hospital cancer registries since 1989 and now has almost 26 million records. 

Frequently Asked Questions

Data Collection Methodology